TY - JOUR
T1 - Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting
AU - Capitini, Christian M.
AU - Cooper, Laurence J.N.
AU - Maarten Egeler, R.
AU - Handgretinger, Rupert
AU - Locatelli, Franco
AU - Sondel, Paul M.
AU - Mackall, Crystal L.
PY - 2009
Y1 - 2009
N2 - The first annual conference on immunotherapy in pediatric oncology was field in Bethesda, MD, from September 9 to 10, 2008 to discuss the state-of-the-art of immunotherapeutic strategies currently being explored in pediatric oncology. Major topics included targeting cell surface receptors, understanding and improving T-cell-based therapies, augmenting innate immune strategies, and enhancing graft-versus-leukemia for pediatric malignancies. As can be seen in the summaries of the individual presentations, significant progress has been made in developing preclinical models of pediatric tumors and a variety of novel immunobiologic therapies are approaching, or already in, the clinic. Although there is much excitement about the potential utility of these agents, a great deal of challenges lie ahead in improving the efficacy of each of these modalities and getting them to patients in a timely fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies.
AB - The first annual conference on immunotherapy in pediatric oncology was field in Bethesda, MD, from September 9 to 10, 2008 to discuss the state-of-the-art of immunotherapeutic strategies currently being explored in pediatric oncology. Major topics included targeting cell surface receptors, understanding and improving T-cell-based therapies, augmenting innate immune strategies, and enhancing graft-versus-leukemia for pediatric malignancies. As can be seen in the summaries of the individual presentations, significant progress has been made in developing preclinical models of pediatric tumors and a variety of novel immunobiologic therapies are approaching, or already in, the clinic. Although there is much excitement about the potential utility of these agents, a great deal of challenges lie ahead in improving the efficacy of each of these modalities and getting them to patients in a timely fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies.
KW - T cells
KW - cell surface receptors
KW - graft-versus-leukemia
KW - immunotherapy
KW - innate immunity
KW - T cells
KW - cell surface receptors
KW - graft-versus-leukemia
KW - immunotherapy
KW - innate immunity
UR - http://hdl.handle.net/10807/258219
U2 - 10.1097/MPH.0b013e31819a5d8d
DO - 10.1097/MPH.0b013e31819a5d8d
M3 - Article
SN - 1077-4114
VL - 31
SP - 227
EP - 244
JO - JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
JF - JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
ER -